Key Drivers
- Strong Free Cash Flow
- Improving Liquidity Position
- Elevated Debt Load
AIAI Summary
Quest's shift toward higher-value diagnostics, consumer access, and operating leverage supports a stronger growth-and-margin profile, but with DGX above analyst targets and near resistance, investors should wait for proof that pricing and utilization gains can withstand 2027 Medicare reimbursement pressure before adding exposure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Free Cash Flow
- •Improving Liquidity Position
- •Elevated Debt Load
DGX offers strong cash generation and improving margins/liquidity, but elevated valuation, significant debt, and intangible-heavy assets warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Sharp rebound
- •Resistance test
- •Support nearby
DGX rebounded sharply over the last month and remains above its ~$241 average, but a decisive break above $247–$248 is needed to sustain momentum while $237–$240 offers initial support.
Sharp rebound from $231.14 on 2026-09-10 to $247.45 on 2026-09-17
Sentiment & News
Key News Insights:
- •Share Price Highs
- •Alzheimer's Test Expansion
- •Medicare Cut Risk
Quest Diagnostics' strong share momentum and digital/Alzheimer's testing expansion support a defensive growth case, though Medicare reimbursement cuts and debt pressures remain key risks.
DGX's near-term outlook remains constructive, but reimbursement policy developments could materially affect valuation and earnings visibility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings